Immunoproteome analysis of soluble and membrane proteins of *Shigella flexneri* 2457T

Amy V Jennison, Rubhana Raqib, Naresh K Verma

**AIM:** To profile the immunogenic proteins of *Shigella flexneri* (*S. flexneri*) expressed during human infection using a proteomic approach.

**METHODS:** Soluble and membrane protein extractions of *S. flexneri* 2457T were separated by two-dimensional gel electrophoresis (2-DE). Proteins were transferred to PVDF membrane and immunoblotted with sera from shigellosis patients. Reactive protein spots were matched to Coomassie stained gels run in parallel, cut out and trypsin digested. Matrix-assisted laser desorption/ionization time of flight-mass spectrometry (MALDI-TOF-MS) was used to determine the peptide mass fingerprints, which were searched in the MASCOT database to identify the protein.

**RESULTS:** A total of 8 immunoreactive proteins were successfully identified from the Coomassie stained gels in three repeats. Six of these proteins have not previously been reported as immunogenic in *S. flexneri*. These proteins could be potential candidates for vaccine or attenuation studies.

**CONCLUSION:** Soluble and membrane proteins of *S. flexneri* 2457T have been screened by 2-DE and immunoblotting with sera from shigellosis patients. Eight proteins are identified as immunogenic.

© 2006 The WJG Press. All rights reserved.

**Key words:** *Shigella flexneri*; Immunogenetics; Vaccine antigen; Immunoblotting

Jennison AV, Raqib R, Verma NK. Immunoproteome analysis of soluble and membrane proteins of *Shigella flexneri* 2457T. *World J Gastroenterol* 2006; 12(41): 6683-6688
date, a proteomic study of detectable immunoreactive proteins from natural *Shigella* infection of humans has not been reported. It is possible to identify antigens from two-dimensional gels using immunoproteomics, where proteins of a particular pathogen are separated by two-dimensional electrophoresis (2D-E) and blotted onto membranes and probed with patients’ sera. Subsequent matching and identification of any reactive protein spots generates an immunoproteome for the organism in question. This technique was initially used to visualize the antigens of *Borrelia garinii* and has since been used for a number of microorganisms including *S. aureus*, *H. pylori* and *C. albicans*. Similar studies have recently been performed with *S. flexneri* protein probed with sera from immunized mice or rabbits. However, shigellosis is not a natural disease of mice or rabbits and it remains unclear what use immunoproteome data from laboratory animals will be in the study of human *Shigella* infection. Consequently the generation of an immunoproteome for *S. flexneri* with sera from human shigellosis patients would ultimately be a desirable tool for future vaccine and virulence research.

In this paper, we report the use of immunoproteomics to visualize and identify immunogenic *S. flexneri* 2457T serotype 2a soluble and membrane proteins, which are reactive to sera from *S. flexneri* infected patients.

**MATERIALS AND METHODS**

**Bacterial cell culture**

*S. flexneri* 2457T was grown in Luria Bertani broth overnight at 37°C in a shaking incubator. Overnight cultures were diluted 1:100 and shaken at 140 rpm until an OD$_{600}$ of 0.5 was reached.

**Isolation of soluble proteins**

Cultures at OD$_{600}$ 0.5 were pelleted by centrifugation at 14 000 g, 4°C for 10 min. Pellets were washed in wash buffer (68 mmol/L NaCl, 2 mmol/L KCl, 1.5 mmol/L KH$_2$PO$_4$, 9 mmol/L NaH$_2$PO$_4$) and pelleted again. The pellet was resuspended in lysis buffer (8 mol/L urea, 4% w/v CHAPS, 1% w/v DTT, 0.8% 3/10 ampholytes, 35 mmol/L Trizma, 5 mmol/L EDTA, 1 mmol/L PMSF) and sonicated on ice at constant duty and an output of 8 for 10 × 10 s with 20 s breaks by a Branson 450 Sonifier (Branson Ultrasonics Corporation, Danbury, CT, USA). Unbroken cells and debris were removed by centrifugation at 10 000 × g for 1 h at 10°C. The supernatant was collected and stored at -80°C until required. The protein concentration of the remaining supernatant was determined by Bradford assay using BSA suspended in lysis buffer as the standard.

**Isolation of outer membrane proteins**

For the extraction of membrane proteins the method was modified from Molloy et al., with the following changes. Cultures at OD$_{600}$ of 0.5 were collected by spinning at 1400 × g for 10 min. Harvested cells were resuspended in wash buffer (68 mmol/L NaCl, 2 mmol/L KCl, 1.5 mmol/L KH$_2$PO$_4$, 9 mmol/L NaH$_2$PO$_4$) and spun again. The pellet was resuspended in 50 mmol/L Tris-HCl pH 7.3 containing 0.2 g/L DNase I. The cells were disrupted by sonication as described above and unbroken cells and cell debris were removed by centrifugation at 6000 g for 10 min. The supernatant was collected and the pellet was resuspended in 50 mmol/L Tris-HCl pH 7.3 and submitted to sonication and centrifugation again. The supernatants were pooled, carbonate treated and collected as described by Molloy et al. The collected membrane proteins were resuspended in 2% ASB-14, 1% DTT, 7 mol/L urea, 2 mol/L thiourea, 0.5% 3/10 ampholytes and stored at -80°C.

**Two-dimensional electrophoresis**

For the first dimension isoelectric focusing, 11 cm Immobiline Dry Strips with the pH gradient 4-7 were used (Amersham Pharmacia Biotech, Uppsala, Sweden). Strips were rehydrated for 16 h in 200 µL of rehydration solution (8 mol/L urea, 0.5% w/v CHAPS, 0.15% w/v DTT, 0.5% v/v Biolyte 3-10 carrier ampholytes and a trace of bromophenol blue). Strips were placed in a Multiphor II horizontal electrophoresis system (Amersham Pharmacia Biotech, Uppsala, Sweden) and 200 µL samples (about 1000 µg) of soluble and membrane protein preparations were cup loaded at the anode. Focussing was run at 20°C, 1 mA, 5 W at the following voltage gradients: 1 min 150 V, 20 min 150 V, 20 min 200 V, 2 h 300 V, 2 h on a linear gradient to 3500 V and 20 h at 3500 V. After isoelectric focussing, the strips were treated with equilibration solution I (40% v/v glycerol, 0.05 mol/L Tris-HCl pH 6.8, 6 mol/L urea, 2% w/v SDS and 2% w/v DTT) for 10 min and 10 min in equilibration solution II (40% v/v glycerol, 0.05 mol/L Tris-HCl pH 6.8, 6 mol/L urea, 2% w/v SDS and 2% w/v iodoacetamide and 0.005% bromophenol blue). Second dimension SDS-PAGE was performed on a horizontal Multiphor II electrophoresis system using precast Excel Gels with 12%–14% acrylamide gradient (Amersham Pharmacia Biotech, Uppsala, Sweden). Twin gels were loaded with a soluble protein and a membrane protein 11 cm Immobiline strip. Low molecular range markers (Amersham Pharmacia Biotech, Uppsala, Sweden) were loaded between the strips. Electrophoresis was performed at 200 V for 1 h 45 min and 600 V for 4–6 h, until the bromophenol blue front reached the edge of the gel. One of the twin gels was stained with CBB G250. Approximately 150 spots were visualized for the soluble protein preparation and 25 for the membrane preparation.

**Immunoblotting**

The remaining gel was used for immunoblotting, where the proteins were transferred to PVDF membrane using the horizontal semi-dry electrophoretic Pharmacia LKB NovaBlot system (Amersham Pharmacia Biotech, Uppsala, Sweden) at a constant current of 0.8 mA/cm². A reference map of proteins was produced by amido black staining of the membrane. The image was scanned before the membrane was destained.

The membrane was blocked with 5% skim milk powder/PBS/0.1% Tween-20 overnight at 4°C, washed three times with PBS/0.05% Tween-20 for 10 min each.
and incubated overnight at 4°C with 1:100 dilution of pooled sera from five *S. flexneri* patients (International Centre for Diarrhoecal Disease, Bangladesh) diluted in 1% skim milk powder/PBS/0.1% Tween-20. The serum samples were obtained by the International Centre for Diarrhoecal Disease, Bangladesh, from *S. flexneri* shigellosis patients during the acute stage of shigellosis, 3-6 d after the onset of diarrhoea. Sera were pooled due to the limited volume of patients’ sera available. The membrane was washed three times with PBS/0.05% Tween-20 for 10 min and incubated with 1:100000 dilution of sheep anti-human Ig-HRP (Chemicon International, Temecula, CA, USA) in 1% skim milk powder/PBS/0.1% Tween-20 for 1.5 h, at 4°C. The membrane was washed with PBS/0.05% Tween three times and twice with PBS, before being incubated for 5 min with SuperSignal West Pico Chemiluminescent Substrate (Pierce Biotechnology Inc, Rockford, IL, USA) and developed by autoradiography. Membranes were stripped as per Jungblut and Bumann[25] and reprobed as above using sera from five healthy individuals obtained from the Australian Red Cross Blood Bank.

**Peptide mass fingerprinting**

Developed films, scanned pictures of the amido black stained membrane and the Coomassie stained twin gel were superimposed and compared using Adobe Photoshop® and transparencies prepared from the images. Protein spots from the Coomassie gel, which aligned to spots on the film, were excised from the gel. Some samples were sent for matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) analysis at the Australian Proteome Analysis Facility (APAF) at Macquarie University. Alternatively protein spots were digested with trypsin for 16 h at 37°C and the peptide mixture was mixed (1:1) with a saturated α-cyano-4-hydroxycinnamic acid solution in 30% acetonitrile-0.07% trifluoroacetic acid. One µL of mixture was spotted onto a sample template plate and mass spectra were obtained at the Research School of Biological Sciences (RSBS) Molecular Biology Facility (Australian National University) with an Omniflex mass spectrometer (Bruker Daltonics, Billerica, USA). Autolysing trypsin peptide 2211.1 Da was used as an internal calibration. Post-analysis data processing was done using Xmass™ software (Bruker Daltonics, Billerica, USA). Searches were performed against the MSDB database with the MASCOT peptide mass fingerprint search engine (Matrix Science)[26]. In all significant matches, the top match was a *S. flexneri* protein.

**RESULTS**

**Soluble protein profile**

Figure 1A shows the CBB G250 stained 2D-E gel of *S. flexneri* membrane and soluble protein preparations. This gel is a representative example of the three independent repeats of protein extraction and 2D electrophoresis performed for this study. Approximately 150 soluble protein spots were visualized from about 1 mg of soluble protein preparation applied to the CBB G250 stained gel. A twin gel was used for electroblotting onto PVDF membrane and membranes were transiently stained with amido black to aid in subsequent spot matching to the CBB gel. The membrane was probed with sera from *S. flexneri* patients and a map of immunoreactive proteins was visualized by chemiluminescence. The pattern of immunogenic proteins is shown on the film in panel B of Figure 1. This film is a representative of the three films from the immunoblot repeats. A total of 6 immunogenic proteins could be matched in each of the three repeats to a corresponding protein spot on the CBB G250 gel. These proteins were identified using peptide mass fingerprinting. The membranes from all three repeats were stripped and reprobed with sera from healthy volunteers. The resulting films had very little signal and displayed only 2 or 3 reactive spots (data not shown), none of which could be aligned to a visible *S. flexneri* protein spot on the CBB G250 gel and were not analysed by peptide mass fingerprinting.

**Outer membrane protein profile**

The outer membrane protein extractions, stained by CBB G250, are shown on the representative gel in Figure 1A. Approximately 25 proteins were visualized for each of the three protein preparations. The film displaying the immunoreactive membrane proteins to *S. flexneri* patients’ sera is shown in panel B of Figure 1. It was possible to match five immunogenic spots on the film to the corresponding protein spots on the twin CBB G250 gel. Membranes, from each of the three repeats, were stripped and reprobed with control sera from healthy individuals. However, no immunoreactive spots were detected against the membrane protein preparations.

Figure 1 A: Coomassie blue stained 2D gel of *S. flexneri* membrane and soluble protein preparations; B: Immunoblot of *S. flexneri* membrane and soluble protein preparations. Circles indicate immunoreactive spots successfully matched and identified from the Coomassie gel (A). Numbers correspond to Table 1.
Identified immunoreactive proteins

Protein spots, which corresponded to an immunogenic spot from the immunoblot film were excised and submitted to in-gel tryptic digestion and MALDI-TOF. Of these protein spots, eight proteins were successfully identified by peptide mass matching. All eight proteins were shown as both the protein spot on the 2-DE gel and as the corresponding immunogenic spot on the matching film (Figure 1). Table 1 lists the identified proteins from the soluble and membrane preparations. Five of the eight proteins were detected in the membrane protein extraction: OmpA, AnsB, ToIC, Ggt, ToIB. However, OmpA, ToIC and AnsB were also detected as immunogenic spots in the soluble protein extraction. Three proteins were identified exclusively as immunogenic soluble proteins: GroEL, Spa33 and IpaD. OmpA, ToIC, IpaD and Spa33 were detected as immunogenic spots numerous times in the same gel, suggesting they are occurring as protein series, with each variation retaining its antigenic characteristics.

DISCUSSION

A total of eight proteins were successfully identified in three separate 2D-E gel immunoblots with a pool of S. flexneri patients’ sera. Of the eight immunogenic proteins, only two are known to be immunoreactive for S. flexneri: IpaD and OmpA. IpaD is a secreted protein essential for entry into epithelial cells and has been reported to be antigenic in a number of S. flexneri studies.[8,20-28]. However, it remains unclear whether anti-IpaD antibodies contribute to protective immunity in humans.[2]. All four Ipa proteins have previously been reported to be immunogenic in natural infection, yet IpaA, IpaB and IpaC were not detected as antigens in this immunoproteome study.[8] A two-dimensional proteome map of S. flexneri 2457T generated by Liao et al.[8] was also unsuccessful in detecting any of the Ipa proteins besides IpaD. Likewise, all three previous immunoproteomic studies for S. flexneri were unsuccessful in detecting any of the Ipa protein series as immunogenic.[20-22]. It is possible that IpaA, IpaB and IpaC were not present in the 2-DE gels at sufficient protein concentrations for detection by the CBB G250 staining. The numbers of S. flexneri protein spots visualized on the CBB G250 gels were quite low, possibly due to insolubility problems during the protein extractions or low resolution of the pI 4-7 IEF strips used. A number of immunogenic spots detected on the immunoblot X-ray film could not be matched to a corresponding Coomassie stained spot, suggesting that some proteins were simply present at concentrations not detectable by CBB G250. It would be possible to improve the resolution of the 2D-E gels by using silver staining which increases the sensitivity of protein detection by an order of magnitude over CBB. Alternatively, fluorescent stains that are readily compatible with MALDI-TOF could increase the sensitivity of protein detection.

OmpA is a 35 kDa outer membrane protein and was identified a number of times during the immunoproteome analysis. OmpA is most probably a constituent of the major outer membrane proteins described as immunoreactive in Shigella patients and thus is known to be immunogenic.[9]

The other six proteins have not previously been shown to be reactive to antibodies found in patients with a natural S. flexneri infection. However, the E. coli L-asparaginase II (AnsB) protein which shares 99.1% identity with S. flexneri AnsB, and the highly conserved chaperonin GroEL, in a number of bacterial species, have been reported as antigenic[31,32]. The remaining four proteins are potential candidates for Shigella-specific antigenic and immunization studies and could ultimately be useful in the development of new Shigella vaccines. However, being immunogenic does not necessarily mean that an antigen is capable of producing a protective immune response, with as little as 2.5% of antigens displaying protective properties[33]. Alternatively, because these antigenic proteins are clearly expressed during invasion of the host, as they are recognized by the host immune response, they may be important for pathogenesis. Any such proteins may be potential virulence factors and could be used in bacterial attenuation of live vaccine strains.

Membrane and surface associated proteins are often immunogenic due to their likelihood of being exposed to the host’s immune response. A number of the immunogenic proteins identified in this study are membrane or surface displayed proteins. Three outer membrane proteins were identified as immunogenic, OmpA, ToIC and ToIB. ToIC plays a role in outer
membrane permeability and has been used as an epitope carrier in *Salmonella*, while TolB is involved in the import of colicins[34,35]. Spa33 is a surface displayed protein involved in the regulation of the IpaB and IpaC secretion from the cell, an important virulence step during *S. flexneri* invasion[96]. Although Spa33 was identified as a significant match by MASCOT with peptide mass fingerprints produced from the corresponding protein spot, the observed molecular weight was inconsistent with the predicted mass. Spa33 was observed as a 68 kDa protein in Figure 1 but the predicted size was 33.4 kDa. This size discrepancy may be due to Spa33 interacting with itself as a dimer or possibly forming a complex with a protein which was not detected in the consequent peptide mass fingerprinting. There is no evidence in the literature for Spa33 forming homodimers although it is possible that Spa33 interacts with Spa32, which is predicted to be a protein of 35.6 kDa[96].

Often periplasmic proteins are immunogenic, particularly when they are found extracellularly where they are exposed to the host’s immune response. In this study, two metabolic periplasmic enzymes, Ggt and AnsB were identified; gamma glutamyltranspeptidase (Ggt) is a periplasmic enzyme, which is essential for the utilization of gamma-glutamyl peptide as an amino acid source and L-asparaginase II (AnsB) is a high affinity periplasmic enzyme, induced by anaerobiosis[37,38]. Both AnsB and Ggt were identified from the membrane extraction of *S. flexneri* proteins. It is possible that the membrane preparation contains some contaminating soluble proteins. The protein sequence of Ggt contains a signal peptide and has 99.7% aa identity to *E. coli* K12 Ggt which also contains a signal peptide and localizes to the periplasm[99]. However, the mammalian form of Ggt is linked to the plasma membrane and *Neisseria meningitidis* Ggt associates with the inner membrane, suggesting that the presence of *S. flexneri* Ggt in the membrane fraction may not simply be inefficient separation of membrane proteins from soluble proteins but perhaps due to a membrane association of the protein.

Control immunoblots were performed with each of the three membranes, using sera from five healthy individuals. It can be assumed that these five individuals have previously been exposed to commensal gut microflora, including *E. coli* of which *Shigella* is a clone[40]. Consequently, the control sera should contain antibodies reactive to *E. coli* and other commensal bacterial proteins, which may potentially recognize homologous *Shigella* proteins[41]. Thus, the control immunoblots could be used as a baseline, where any *Shigella* proteins recognized by the control sera were most likely reacting with antibodies raised against the commensal gut microflora. Consequently, immunogenic proteins, which were only detected in the *Shigella* immunoblots and not in control blots could be considered as part of a *Shigella* specific immune response. The control immunoblots did not generate any spots that aligned to the eight *S. flexneri* protein spots from the *S. flexneri* patients, suggesting that the eight antigenic proteins identified reacted to anti-*Shigella* specific antibodies in the *Shigella* patients’ sera.

This is the first *S. flexneri* proteomic study of the immunoreactive proteins expressed during natural *Shigella* infection of humans. A similar study has been performed using immunized mouse sera in 2-DE gel immunoblots of *S. flexneri* outer membrane protein and soluble protein preparations. That study identified 13 seroreactive proteins, none of which correspond with our identified proteins[90]. Another group has visualized immunoproteomes for *S. flexneri* protein probed with sera from immunized rabbits[20,22]. Only two proteins, OmpA and TolC identified as immunoreactive in the present study were also detected in that work. As *S. flexneri* does not naturally infect or cause shigellosis-like symptoms in mice or rabbits and the experimental animals were not immunized mucosally, it remains unclear how relevant these seroreactive proteins are to the natural human anti-*S. flexneri* immune response.

In this study, eight proteins with reactivity to sera from patients with *S. flexneri* infection were identified using immunoproteomics. Six of these identified proteins have not previously been reported as immunogenic in *S. flexneri* natural infection. These immunoreactive proteins could be novel candidates for vaccine development. Additionally, such proteins have great potential for roles in virulence, as it seems likely they are expressed by the bacteria during the infection of the host, making them prospective attenuation targets for live vaccine construction.

ACKNOWLEDGMENTS

We would like to thank Dr. Ulrike Mathesius for her assistance with the 2D electrophoresis work, the Australian Red Cross Blood Bank for providing the control sera samples and Julie Christie of RSBS-MBF for technical advice and assistance with the MALDI-TOF.

REFERENCES

1. Kotloff KL, Winickoff JP, Iannov B, Clemens JD, Swedlow DL, Sansonetti PJ, Adak GK, Levine MM. Global burden of *Shigella* infections: implications for vaccine development and implementation of control strategies. *Ball World Health Organ* 1999; 77: 651-666.

2. Menard R, Sansonetti PJ, Parsot C. Nonpolar mutagenesis of the ipa genes defines IpAB, IpAC, and IpD as effectors of *Shigella flexneri* entry into epithelial cells. *J Bacteriol* 1993; 175: 5899-5906.

3. Sasakawa C, Kamata K, Sakai T, Makino S, Yamada M, Okada N, Yoshikawa M. Virulence-associated genetic regions comprising 31 kilobases of the 230-kilobase plasmid in *Shigella flexneri* 2a. *J Bacteriol* 1988; 170: 2480-2484.

4. Way SS, Borczuk AC, Goldberg MB. Thymic independence of adaptive immunity to the intracellular pathogen *Shigella flexneri* serotype 2a. *Infect Immun* 1999; 67: 3970-3979.

5. Mel DM, Arsic BL, Nikolic BD, Radovanovic ML. Studies on vaccination against bacillary dysentery. 4. Oral immunization with live monotypic and combined vaccines. *Ball World Health Organ* 1968; 39: 375-380.

6. Jennison AV, Verma NK. *Shigella flexneri* infection: pathogenesis and vaccine development. *FEBS Microbiol Rev* 2004; 28: 43-58.

7. DuPont HL, Hornick RB, Snyder MJ, Libonati JP, Formal SB, Gangarosa EJ. Immunity in shigellosis. II. Protection induced by oral live vaccine or primary infection. *J Infect Dis* 1972; 125: 12-16.

8. Oaks EV, Hale TL, Formal SB. Serum immune response to *Shigella* protein antigens in rhesus monkeys and humans infected with *Shigella* spp. *Infect Immun* 1986; 53: 57-63.
